Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Income from Non-Controlling Interests for 7 consecutive years, with -$3000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Non-Controlling Interests rose 70.0% year-over-year to -$3000.0; the TTM value through Mar 2026 reached -$15000.0, up 82.76%, while the annual FY2025 figure was -$22000.0, 79.82% up from the prior year.
  • Income from Non-Controlling Interests hit -$3000.0 in Q1 2026 for Barinthus Biotherapeutics, up from -$12000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $26000.0 in Q4 2022 and bottomed at -$51000.0 in Q4 2024.
  • Average Income from Non-Controlling Interests over 5 years is -$15176.5, with a median of -$12000.0 recorded in 2025.
  • Year-over-year, Income from Non-Controlling Interests tumbled 950.0% in 2024 and then skyrocketed 145.45% in 2025.
  • Barinthus Biotherapeutics' Income from Non-Controlling Interests stood at $26000.0 in 2022, then plummeted by 76.92% to $6000.0 in 2023, then crashed by 950.0% to -$51000.0 in 2024, then surged by 76.47% to -$12000.0 in 2025, then soared by 75.0% to -$3000.0 in 2026.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods came in at -$3000.0, -$12000.0, and -$5000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.